冠心生脉饮对冠心病患者血清hs-CRP、IL-6、TNF-α及ICAM-1水平的影响研究  

Effect of hs-CRP,IL-6,TNF-α and ICAM-1 in patients with coronary heart disease by Guanxinshengmaiyin

作　　者：于乐[1] 解赢[2] 

机构地区：[1]辽宁中医药大学附属医院心内科,沈阳辽宁110032 [2]鞍山市中医院心内科,鞍山辽宁114000

出　　处：《中国生化药物杂志》2015年第5期108-111,共4页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的探讨冠心生脉饮对于冠心病患者血清hs-CRP、IL-6、TNF-α及ICAM-1水平的影响及其意义。方法选取2013年8月~2014年10月的确诊为冠心病不稳定型心绞痛的患者120例,根据随机数字表法随机分为2组：对照组60例,予常规治疗;实验组60例,予冠心生脉饮治疗。检测两组患者血清中hs-CRP、IL-6、TNF-α及ICAM-1水平的变化、临床疗效、心电图及不良反应,进而对两种治疗方法的疗效进行对比分析。结果与治疗前相比,患者血清hs-CRP、IL-6、TNF-α及ICAM-1水平较低（P〈0.05）;与对照组相比,实验组血清hs-CRP、IL-6、TNF-α及ICAM-1水平较低（P〈0.05）,总有效率（80.00%）较高（P〈0.05）,Ⅱ导联,Ⅲ导联T波深度降低（P〈0.05）,不良反应发生率较低（P〈0.05）。结论冠心生脉饮降低冠心病患者血清中hs-CRP、IL-6、TNF-α及ICAM-1等炎症因子的浓度水平,且其临床疗效明显、不良反应少,对临床治疗冠心病具有重要意义。Objective To investigate effect of hs-CRP,IL-6, TNF-αand ICAM-1 in patients with coronary heart disease by Guanxinshengmaiyin. Methods 120 patients with coronary heart disease were selected and randomly divided into two groups.60 cases in control group were treated by routine treatment, 60 cases in experiment group were on the base of control group with Guanxinshengmaiyin,1 month for a course.hs-CRP, IL-6, TNF-αand ICAM-1 levels, clinical efficacy, electrocardiogram （ ECG ） and adverse reactions were compared after treatment.Results Compared with before treatment, hs-CRP, IL-6, TNF-αand ICAM-1 levels were lower（P〈0.05）.Compared with control group, the serum hs-CRP, IL-6, TNF-αand ICAM-1 levels were lower （ P〈0.05 ） , the total efficiency （ 80.00%） was higher （ P〈0.05 ） , the depth of T wave of lead II and lead III were lower （P〈0.05）,the adverse reactions occur rate was lower（P〈0.05）.Conclusion Guanxinshengmaiyin can reduce serum hs-CRP, IL-6, TNF-αand ICAM-1 levels in patients with coronary heart disease, and has good clinical curative effect, less adverse reaction.

关 键 词：冠心生脉饮 冠心病 HS-CRP IL-6 TNF-Α ICAM-1 

分 类 号：R541[医药卫生—心血管疾病]